Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10716500 | 0.78 | APLNR (0.32) | KMT2AHTTAPLNR | |
| SCHEMBL5316278 | 0.63 | — | — | |
| SCHEMBL23829559 | 0.63 | — | — | |
| SCHEMBL3712447 | 0.62 | APLNR (0.33) | HTTAPLNR | |
| SCHEMBL10414835 | 0.62 | — | — | |
| SCHEMBL3294106 | 0.62 | APLNR (0.36) | KMT2AAPLNR | |
| SCHEMBL2376831 | 0.59 | TMEM97 (0.37) | TMEM97SIGMAR1 | |
| SCHEMBL5593692 | 0.59 | — | — | |
| SCHEMBL10640937 | 0.59 | — | — | |
| SCHEMBL9617196 | 0.57 | APLNR (0.42) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318113-B2 | Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production | OP2 Drugs (FR) | 2022-05-03 | — | — | US | disclosed |
| EP-0724601-A4 | S 3N CHELATING COMPOUNDS FOR THE RADIOLABELING OF LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS | NEORX CORP (US) | 1999-02-03 | — | — | EP | disclosed |
| EP-0724601-A1 | S 3N CHELATING COMPOUNDS FOR THE RADIOLABELING OF LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS | NEORX CORPORATION (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995005398-A1 | S3N CHELATING COMPOUNDS FOR THE RADIOLABELING OF LIGANDS, ANTI-LIGANDS OR OTHER PROTEINS | NEORX CORPORATION (US) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318113-B2 | Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production | FH, TXNRD2, TXN2 | KMT2A 3925/4885HTT 231/4885APLNR 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.